Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 111Pheochromocytoma 33Carcinoma, Neuroendocrine 33Pituitary Neoplasms 28Thyroid Cancer, Papillary 26Paraganglioma 26Adrenocortical Carcinoma 21Neoplasms 19Gastro-enteropancreatic neuroendocrine tumor 19Thyroid Neoplasms 17Adrenal Gland Neoplasms 16Multiple Endocrine Neoplasia Type 1 14Stomach Neoplasms 13Prostatic Neoplasms 13Pancreatic Neoplasms 13Carcinoid Tumor 13Sarcoma 12Lung Neoplasms 12Breast Neoplasms 12Thyroid Carcinoma, Anaplastic 11Adenoma, Islet Cell 11Small Cell Lung Carcinoma 10Ovarian Neoplasms 10Neuroblastoma 10Neoplasm Metastasis 10Colorectal Neoplasms 10Carcinoma, Hepatocellular 10Brain Neoplasms 10Meningioma 9Esophageal Neoplasms 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoid Tumors, Intestinal × Endocrine × Clear all
NCT07087054 2026-04-30

CAREFNDR

Crinetics Pharmaceuticals Inc.

Phase 3 Recruiting
141 enrolled
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡